[{"orgOrder":0,"company":"Wellspring Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Wellspring Ophthalmics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension\/Drops","sponsorNew":"Wellspring Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Wellspring Ophthalmics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Wellspring Ophthalmics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : The Company’s intellectual property portfolio, which includes additional pending patents, covers a broad formulation platform of a unique suspension comprising aqueous, amorphous nanodispersions of cyclosporine.

Brand Name : Cyclosporine-Generic

Molecule Type : Peptide

Upfront Cash : Not Applicable

July 20, 2022

Lead Product(s) : Cyclosporine

Therapeutic Area : Ophthalmology

Highest Development Status : Preclinical

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank